Mark Holodniy

Clinical Focus

• Infectious Disease
• Infectious Diseases

Administrative Appointments

• Member, Medical School Faculty Senate (1999 - 2002)
• Member, Administrative Panel on Biosafety (1995 - 2009)

Honors and Awards

• Divisional Award for Exceptional Contributions in Education in the Division of Infectious Disease, Department of Medicine (2004)
• Infectious Diseases Teaching Award, Division of Infectious Diseases (2004)
• Infectious Diseases Teaching Award, Division of Infectious Diseases (1997)
• HIV Program Clinical Excellence Award, Department of Veterans Affairs (2001)

Professional Education

Postdoctoral Advisees

Aarthi Chary, Philip Grant, Patricia Schirmer

Graduate & Fellowship Program Affiliations

• Medicine
• Infectious Diseases

Community & International Work

• Tri-national OPTIMA Trial 

Research Interests

My research program is currently focused in three areas: 1) translational research (HCV/HIV viral evolution and antiviral resistance prevalence and development), 2) HIV/HCV clinical trials (diagnostic assay/medical device, antiretrovirals, ARVs and immunomodulators), and 3) health services research focusing on cost effectiveness of HIV antibody and ARV resistance testing and ARV utilization and clincal outcome.

Clinical Trials

• Blood Sample Study of viral and Immune Responses to Treatment in People with HIV or Hepatitis C Infections Recruiting

Publications

• Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease Joyce, V, Barnett PG, Bayoumi A, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W,. Journal of Acquired Immune Deficiency Syndromes. 2009; 50 (1): 27-36
• Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. Lloyd RM, Burns DA, Huong JT, Mathis RL, Winters MA, Tanner M, De La Rosa A, Yen-Lieberman B, Armstrong W, Taege A, McClernon DR, Wetshtein JL, Friedrich BM, Ferguson MR, O'Brien W, Feorino PM, Holodniy M. J Clin Microbiol. 2009; 47 (5): 1491-6
• Oseltamivir for treatment and prophylaxis of influenza infection. Schirmer P, Holodniy M. Expert Opin Drug Saf. 2009; 8 (3): 357-71
• Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Jamison RL, Shih MC, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, Warren SR, Gaziano JM, Lavori P. Am J Kidney Dis. 2009; 53 (5): 779-89
• Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Raisch DW, Straight TM, Holodniy M. Pharmacotherapy. 2009; 29 (8): 988-92